FDA Grants Conditional Approval To Interventional Spine’s PercuDyn? System IDE Application
Jul 4th 2008Drug InformationNeurology / Neuroscience
Interventional Spine, Inc. announced that the U.S. Food and Drug Administration has approved the Company’s investigational device exemption (IDE) application for its PercuDyn System for the treatment of degenerative disc disease (DDD). This approval is conditional upon the Company providing some additional information to the FDA. Walter A. Cuevas, Interventional Spine’s CEO, observed, “We are pleased by FDA’s action.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
